PDF herunterladen
Drug Res (Stuttg) 2019; 69(05): 284-290
DOI: 10.1055/a-0672-0707
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Lysimachia Capillipes Inhibit Adipogenesis via Angiogenesis Inhibition

Xiumin Li
1   The Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
,
Yu Xue
1   The Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
,
Liang Pang
2   The College of Physical Education, Minnan Normal University, Zhangzhou, Fujian, China
,
Zhaoshui ShangGuan
3   Central Laboratory, the First Affiliated Hospital of Xiamen University, Xiamen China
,
Yutian Pan
1   The Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 07. März 2018

accepted 06. August 2018

Publikationsdatum:
07. September 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Obesity is a common and increasingly prevalent human condition due to unhealthy diet and less-exercise lifestyle. Development of obesity is associated with substantial modulation of adipose tissue structure. The expansion of adipose tissue is linked to the development of its vasculature, and modulation of angiogenesis may have the potential to impair adipose tissue development. In this study, we used obesity model of zebrafish fed by egg yolk to investigate the effect of Lysimachia capillipes on the obesity. The results showed that Lysimachia capillipes inhibited angiogenesis of adipose tissue in transgenic zebrafish Tg (Fli 1: EGFP), which was similar to surppressing effect of TNP-470, which was accompanied by decreased Oil Red O staining of the zebrafish. The treatment of Lysimachia capillipes reduced expression of MTP significantly, but modestly reduced expression of Ppar g, FABP10a, and CD36 level through ISH, which was accordant with the results by PCR analysis. The study proved that Lysimachia capillipes might possess novel therapeutic properties for prevention and treatment of obesity.

Key words

Lysimachia capillipes - adipogenesis - angiogenesis - fat metabolism
 

  • References

  • 1 Tingaud-Sequeira A, Ouadah N, Babin PJ. Zebrafish obesogenic test: A tool for screening molecules that target adiposity. J Lipid Res 2011; 52: 1765-1772
    CrossrefPubMedGoogle Scholar
  • 2 Haque MR, Ansari HS. Anti-obesity effect of Arq Zeera and Its main components thymol and cuminaldehyde in high fat diet induced obese rats. Drug Res 2018; Apr 10 DOI: 10.1055/a-0590-1956.. [Epub ahead of print]
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 3 Nakagami H. The mechanism of white and brown adipocyte differentiation. Diabetes & Metabolism Journal 2013; 37: 85-90
    CrossrefPubMedGoogle Scholar
  • 4 Sanchez-Gurmaches J, Guertin DA. Adipocyte lineages: Tracing back the origins of fat. Biochim Biophys Acta 2014; 1842: 340-351
    PubMedGoogle Scholar
  • 5 Kolonin MG, Saha PK, Chan L. et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004; 10: 625-632
    CrossrefPubMedGoogle Scholar
  • 6 De Falco S. Antiangiogenesis therapy: An update after the first decade. The Korean Journal of Internal Medicine 2014; 29: 1-11
    CrossrefPubMedGoogle Scholar
  • 7 Ledoux S, Quequiner I, Msika S. et al. Angiogenesis associated with visceral and subcutaneous adipose tissue in severe human obesity. Diabetes. 2008; 57: 3247-3257
    CrossrefPubMedGoogle Scholar
  • 8 Rupnick MA, Panigrahy D, Zhang CY. et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002; 99: 10730-10735
    CrossrefPubMedGoogle Scholar
  • 9 Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nature reviews. Drug discovery. 2010; 9: 107-115
    CrossrefPubMedGoogle Scholar
  • 10 Daquinag AC, Zhang Y, Kolonin MG. Vascular targeting of adipose tissue as an anti-obesity approach. Trends in pharmacological sciences 2011; 32: 300-307
    CrossrefPubMedGoogle Scholar
  • 11 Fei ZH, Wu K, Chen YL. et al. Capilliposide Isolated from Lysimachia capillipes Hemsl. Induces ROS Generation, Cell Cycle Arrest, and Apoptosis in Human Nonsmall Cell Lung Cancer Cell Lines. Evid Based Complement Alternat Med 2014; 2014: 497456
    PubMedGoogle Scholar
  • 12 Liang B, Zhang L, Tian J. et al. Isolation and characterization of two new saponins from Lysimachia capillipes. Carbohydrate research. 2006; 341: 2444-2448
    CrossrefPubMedGoogle Scholar
  • 13 Xie C, Xu LZ, Luo XZ. et al. Flavonol glycosides from Lysimachia capillipes. Journal of Asian Natural Products Research 2002; 4: 17-23
    CrossrefPubMedGoogle Scholar
  • 14 White HM, Acton AJ, Considine RV. The angiogenic inhibitor TNP-470 decreases caloric intake and weight gain in high-fat fed mice. Obesity (Silver Spring) 2012; 20: 2003-2009
    CrossrefPubMedGoogle Scholar
  • 15 Hines J, Ju R, Dutschman GE. et al. Reversal of TNP-470-induced endothelial cell growth arrest by guanine and guanine nucleosides. J Pharmacol Exp Ther 2010; 334: 729-738
    CrossrefPubMedGoogle Scholar
  • 16 Meguro S, Hasumura T, Hase T. Body fat accumulation in zebrafish is induced by a diet rich in fat and reduced by supplementation with green tea extract. PLoS One. 2015; 10: e0120142
    CrossrefPubMedGoogle Scholar
  • 17 Flynn 3rd EJ, Trent CM, Rawls JF. Ontogeny and nutritional control of adipogenesis in zebrafish (Danio rerio). J Lipid Res 2009; 50: 1641-1652
    CrossrefPubMedGoogle Scholar
  • 18 Misra M. Obesity pharmacotherapy: Current perspectives and future directions. Current Cardiology Reviews 2013; 9: 33-54
    PubMedGoogle Scholar
  • 19 Hosogai N, Fukuhara A, Oshima K. et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007; 56: 901-911
    CrossrefPubMedGoogle Scholar
  • 20 Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related pathologies: The macro- and microcirculation of adipose tissue. The FEBS Journal 2009; 276: 5738-5746
    CrossrefPubMedGoogle Scholar
  • 21 Flier JS. Obesity wars: Molecular progress confronts an expanding epidemic. Cell. 2004; 116: 337-350
    CrossrefPubMedGoogle Scholar
  • 22 Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest 2011; 121: 2094-2101
    CrossrefPubMedGoogle Scholar
  • 23 Polvani S, Tarocchi M, Tempesti S. et al. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World Journal of Gastroenterology 2016; 22: 2441-2459
    CrossrefPubMedGoogle Scholar
  • 24 Chawla A. Control of macrophage activation and function by PPARs. Circ Res. 2010; 106: 1559-1569
    CrossrefPubMedGoogle Scholar
  • 25 Monsalve FA, Pyarasani RD, Delgando-Lopez F. et al. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm. 2013; 2013: 549627
    PubMedGoogle Scholar
  • 26 Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: Is increased fatness commensurate with long-term efficacy?. Int J Obes Relat Metab Disord 2003; 27: 147-161
    CrossrefPubMedGoogle Scholar
  • 27 Den Broeder MJ, Kopylova VA, Kamminga LM. et al. Zebrafish as a model to study the role of peroxisome proliferating-activated receptors in adipogenesis and obesity. PPAR research 2015; 2015: 358029
    PubMedGoogle Scholar
  • 28 Schulman IG. Nuclear receptors as drug targets for metabolic disease. Advanced Drug Delivery Reviews 2010; 62: 1307-1315
    CrossrefPubMedGoogle Scholar
  • 29 Zhang X, Young HA. PPAR and immune system – what do we know?. International Immunopharmacology. 2002; 2: 1029-1044
    CrossrefPubMedGoogle Scholar
  • 30 Majdalawieh A, Ro HS. PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. Nuclear Receptor Signaling 2010; 8: e004
    PubMedGoogle Scholar
  • 31 Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998; 391: 82-86
    CrossrefPubMedGoogle Scholar